ArticleClinical parkinsonism & related disorders2026
Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is a new device-aided therapy for advanced Parkinson's disease (PD), but real-world implementation experience, particularly in patients with prior deep brain stimulation (DBS), remains limited. Objectives: To describe a clinical workflow for LDp/CDp implementation and report outcomes from the first 50 consecutive patients. Methods: Quality improvement report based on retrospective chart review at a tertiary movement disorders center between January 2025 and April 2026. Clinical management lessons were synthesized into an implementation workflow, and clinical response was assessed using the Clinician Global Impression of Change (CGI-C). Results: Median age was 68 years, disease duration 14 years, and baseline levodopa equivalent daily dose 1108 mg; 37 patients (74%) were male, 25 (50%) had prior DBS, and six (12%) had transitioned from levodopa-carbidopa intestinal gel. Patients required a median of 4 visits to reach stable dosing. Manufacturer-predicted and final optimized median base infusion rates were similar (medians 0.38 vs 0.39 mL/h), although individualized titration was required in most patients. Clinician-assigned CGI-C ratings were in the improved range in 78% (38/49) of patients for motor fluctuations and 63% (31/49) for dyskinesia. Over a median follow-up of 7.2 months, 41 patients (82%) remained on therapy; skin reactions occurred in 46%, six patients (12%) discontinued, and three patients (6%) died. Among patients with DBS, median total stimulation current was 4.4 mA before and 4.0 mA after optimization; 7/25 (28%) had reductions. Conclusions: We describe a local clinical workflow used to implement LDp/CDp in routine care, including among patients with existing DBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.